Business, energy, technology, markets and global industry news from Business News Today

darolutamide

PharmaDeviceNews darolutamide
Representative image: Targeted prostate cancer treatment enters focus as AstraZeneca’s Truqap approval highlights PTEN-deficient metastatic disease, biomarker testing, and the future of precision oncology.
Pharma & Biotech

Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial

Bayer's NUBEQA improved four-year metastasis-free survival to 95% in high-risk prostate cancer. Overall survival evidence remains immature.

Read More
Representative image of an oncology consultation for advanced prostate cancer treatment, as Bayer’s NUBEQA cognitive decline data from the ARACOG trial raises new questions about quality-of-life differences between darolutamide and enzalutamide.
Pharma & Biotech

Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data?

Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.

Read More
Pharma & Biotech

NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals

Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.

Read More